“Phase 2 Confirmatory Study of Cemiplimab (350 Mg IV Q3W) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Study 1540 Group 6”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s175, https://doi.org/10.25251/skin.7.supp.175.